Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc

In a report released yesterday, Vikram Malhotra from Mizuho Securities reiterated a Buy rating on Prologis, with a price target of $138.00. The com...

Mizuho Securities Reaffirms Their Buy Rating on Prologis (PLD)

Kodak ( ($KODK) ) has shared an update. On December 2, 2025, Kodak completed the reversion process for $1.023 billion in excess pension assets from...

Kodak Strengthens Balance Sheet with Pension Reversion

In a report released today, Ronald Kamdem from Morgan Stanley maintained a Buy rating on Prologis, with a price target of $120.00. According to Tip...

Morgan Stanley Sticks to Their Buy Rating for Prologis (PLD)

Prologis ( ($PLD) ) has shared an update. On November 24, 2025, Prologis, Inc. announced that Damon Austin will assume the role of Chief Developmen...

Prologis Appoints New Chief Development Officer

Prologis ( ($PLD) ) has shared an announcement. On November 24, 2025, Prologis, Inc. announced that Damon Austin will assume the role of Chief Deve...

Barclays analyst Gena Wang maintained a Hold rating on Kodiak Sciences today and set a price target of $17.00. Wang covers the Healthcare sector, f...

Barclays Sticks to Its Hold Rating for Kodiak Sciences (KOD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spero Therapeutics (SPRO – Research Report), Kodia...

Current Quarter	$-1.06	Next Quarter	$-0.87
Current Year	$-4.22	Next Year	$-3.72
QoQ Growth	+17.9%	YoY Growth	+11.8%
3Y EPS CAGR	N/A	Target Price	$21.29
Consensus	Buy	Upside	-10.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KOD	$23.81	-1.33%	423.35K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KOD	$23.81	-1.3%	423.35K
3
4
5
6

KOD

KOD

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get Kodiak Sciences Inc Data in Excel

Get Kodiak Sciences Inc Data in Excel